Products for Research Use Only

SN-38-d3

CAT: 0804-HY-13704S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13704S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SN-38-d3 is the deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively[1][2][3][4].
CAS Number
718612-49-8
Product Name Alternative
NK012-d3
UNSPSC
12352005
Hazard Statement
H301
Target
ADC Payload; Autophagy; Topoisomerase
Type
Isotope-Labeled Compounds
Related Pathways
Antibody-drug Conjugate/ADC Related; Autophagy; Cell Cycle/DNA Damage
Field of Research
Cancer
Purity
98.79
Solubility
DMSO : 25mg/mL (ultrasonic)
Smiles
[2H]C([2H])([2H])CC1=C2C(C(N3C2)=CC([C@](O)(C(OC4)=O)CC)=C4C3=O)=NC5=CC=C(O)C=C51
Molecular Formula
C22H17D3N2O5
Molecular Weight
395.42
Precautions
H301
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51 (16) :4187-4191.|[3]Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008 Jun;19 (6) :1493-8.|[4]Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a newpair of resistance-associated mutations. J Exp Clin Cancer Res. 2016 Mar 31;35:56.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported